Exhibit 99.1
| | | |
| | Contacts: | | Robert Jaffe/Evan Pondel
PondelWilkinson Inc.
(310) 279-5980 |
LANNETT REPORTS FISCAL 2007 FIRST QUARTER FINANCIAL RESULTS
Philadelphia, PA—November 8, 2006— Lannett Company, Inc. (AMEX: LCI) today reported financial results for the fiscal 2007 first quarter ended September 30, 2006.
For the first quarter of fiscal 2007, net sales rose 62% to $22.0 million from $13.6 million for the fiscal 2006 first quarter. The increase in net sales primarily consisted of higher sales of distributed products, which generally carry lower gross margins. Net income was $1.5 million, or $0.06 earnings per basic and diluted share, which included equity-based compensation expense of $0.2 million, net of tax benefit, or $0.01 per basic and diluted share. This compares with net income of $1.6 million, or $0.07 earnings per basic and diluted share, for the same period in fiscal 2006. Equity-based compensation expense was adopted at the beginning of fiscal year 2006 in accordance with the Statement of Financial Accounting Standards No. 123R.
“While our industry struggles to deal with competitive pressures on sales and margins, we are pleased with the solid top line growth during the first quarter of this year,” “During the quarter, we continued to invest in the company’s future by expanding our drug development program. The leasing of the new facility will help bolster our manufacturing, pharmaceutical development, distribution and warehousing capacities.” said Arthur Bedrosian, Lannett’s president and chief executive officer.
For the first quarter of fiscal 2007, gross profit rose to $9.1 million from $6.8 million in the first quarter of fiscal 2006. Research and development expenses increased to $1.8 million from $1.1 million for the same period in 2006. Selling, general and administrative expenses were $4.4 million, which included a $1.3 million royalty expense related to the sale of distributed products and $0.3 million of equity-based compensation expense, compared with $2.6 million in the first quarter of fiscal 2006. Amortization expense was $446,000 for both periods.
Lannett currently has 13 ANDAs pending at the FDA and 34 products in various stages of development.
About Lannett Company:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at www.lannett.com.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the new facility bolstering capacity, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company’s judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.
# # #
FINANCIAL TABLES FOLLOW
